Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (9150)	3/12/1999 10:40:00 AM
From: aknahow	Respond to of 17367

Yes, you are correct, IMO. I still, however, question how much improvement we have seen in the non treated arm in the U.K. for patients at 8 or above. I continue to question this based on experience in parsing the words of governmental agencies both in and out of the U.S. You know that if you had accomplished this you would provided data proving that the reduction claimed had actually occurred. We have not seen any details demonstrating this and in fact the 1997 data proves that the death rate for meningococcal sepsis was still in the 20% range. Did it decline after that, sans BPI????? We will in any event soon see what has happened in the U.K.

To: Tharos who wrote (9150)	3/12/1999 10:43:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

10K amended available for parsing! So is S 3 registration for sale of shares recently purched by investors. Such registration was part of the original purchase deal. "The BPI Product Platform The Company's current programs are primarily focused on developing novel therapeutic products from bactericidal/permeability-increasing protein ("BPI"). BPI is a naturally-occurring human host-defense protein found in neutrophils (white blood cells). BPI kills certain bacteria. It also binds to and neutralizes endotoxins, molecular components of the cell walls of gram-negative bacteria that can trigger severe complications in infected patients. Furthermore, BPI inhibits angiogenesis (growth of new blood vessels) by binding to and neutralizing heparin, a carbohydrate molecule involved in blood vessel formation. Angiogenesis is an essential component of inflammation and solid tumor growth."

To: Tharos who wrote (9150)	3/12/1999 11:32:00 AM
From: aknahow	Respond to of 17367

FYI challenges facing NHS in U.K. Interesting in terms of progress claimed in meningococcal sepsis. news.bbc.co.uk